1.Solomon, A. an Unusual Receptive Aphasia As a Manifestation of Temporal-Lobe Epilepsy

Bibliography

1.Solomon, A. An unusual receptive aphasia as a manifestation of temporal-lobe epilepsy. Report of a case treated by surgery. N. Engl. J. Med. 257:313-317, 1957.

2.Solomon, A. and Kuhn, L.A. Postural hypotension: Report of a case, with hemodynamic studies of central, peripheral, and pulmonary artery pressures. Am. J. Med. 28:328-332, 1960.

3.Fudenberg, H. and Solomon, A. "Acquired agammaglobulinemia" with auto-immune hemolyticdisease: Graft-versus-host reaction? Vox Sang. 6:68-79, 1961.

4.Solomon, A. The effect of urine hydrolysis on nucleoproteins in normal, leukemoid, and leukemicleukocytes. J. Mt. Sinai Hosp. NY. 28:435-443, 1961.

5.Cline, M.J., Solomon, A., Berlin, N.I., and Fahey, J.L. Anemia in macroglobulinemia. Am. J. Med.34:213-220, 1963.

6.Cohen, S., Solomon, A., Paronetto, F., and Popper, H. Subacute hepatitis in Waldenström'smacroglobulinemia. Am. J. Med.34:256-263, 1963.

7.Solomon, A., Fahey, J.L., and Malmgren, R.A. Immunohistologic localization of gamma-l-macroglobulins, beta-2A-myeloma proteins, 6.6S gamma-myeloma proteins, and Bence Jonesproteins. Blood.21:403-423, 1963.

8.Solomon, A. and Fahey, J.L. Plasmapheresis therapy in macroglobulinemia. Ann. Intern Med. 58:789-800, 1963.

9.Fahey, J.L. and Solomon, A. Two types of -myeloma proteins, 2A-myeloma proteins, 1-macro globulins, and Bence Jones proteins identified by two groups of common antigenic determinants. J. Clin. Invest. 42:811-822, 1963.

10.Solomon, A., Waldmann, T.A., and Fahey, J.L. Metabolism of normal 6.6S -globulin in normalsubjects and in patients with macroglobulinemia and multiple myeloma. J. Lab. Clin. Med. 62:1-17, 1963.

11.Solomon, A. Waldmann, T.A., Fahey, J.L., and McFarlane, A.S. Metabolism of Bence Jones proteins.J. Clin. Invest.43:103-117, 1964.

12.Gill, J.R., Jr., George, J.M., Solomon, A., and Bartter, F.C. Hyperaldosteronism and renal sodium loss reversed by drug treatment for malignant hypertension. N Eng J Med27:1088-1092, 1964.

1. Solomon, A. and Fahey, J.L. Bence Jones proteinemia. Am. J. Med. 37:206-222, 1964.

14.Tomasi, T.B., Jr., Tan, E.M., Solomon, A., and Prendergast, R.A. Characteristics of an immune system common to certain external secretions. J. Exp. Med. 121:101-124, 1965.

15.Solomon, A. Neurological manifestations of macroglobulinemia. In The Remote Effects of Cancer on the Nervous System. Brain, L. and Norris, F.H., Jr., Eds., Grune & Stratton, New York, 1965, pp. 112-124.

16.Fahey, J.L., Barth, W.F., and Solomon, A. Serum hyperviscosity syndrome. J. Am. Med. Assoc. 192:464-467, 1965.

17.Solomon, A., Killander, J., Grey, H.M., and Kunkel, H.G. Low-molecular-weight proteins related to Bence Jones proteins in multiple myeloma. Science . 151:1237-1239, 1966.

18.Kunkel, H.G., Grey, H.M., and Solomon, A. Antigenic variations among myeloma proteins andantibodies. In Immunopathology. IVth International Symposium. Grabar, P. and Miescher, P.A.,Eds., GruneStratton, New York, 1966, pp. 220-228.

19.Zak, F.G., Solomon, A., and Fellner, M.J. Viscero-cutaneous angiomatosis with dysproteinaemicphagocytosis: Its relation to Kaposi's sarcoma and lymphoproliferative disorders. J. Pathol. Bacteriol. 92:594-599, 1966.

20.Rubin, H. and Solomon, A. Cold agglutinins of anti-i specificity in alcoholic cirrhosis. Vox Sang.12:227-230, 1967.

21.Solomon, A. and Kunkel, H.G. A "monoclonal" type, low molecular weight protein related to M-macroglobulins. Am. J. Med. 42:958-967, 1967.

22.Caggiano, V., Cuttner, J., and Solomon, A. Myeloma proteins, Bence Jones proteins and normalimmunoglobulins in multiple myeloma. Blood. 30:265-287, 1967.

23.Solomon, A. Molecular heterogeneity of immunoglobulin-M (M-globulin). J. Immunol. 102:496-506, 1969.

24.Solomon, A. and McLaughlin, C.L. Bence-Jones proteins and light chains of immunoglobulins. I.Formation and characterization of amino-terminal (variant) and carboxyl-terminal (constant) halves.J. Biol. Chem.244:3393-3404, 1969.

25.Solomon, A. and McLaughlin, C.L. Bence Jones proteins and light chains of immunoglobulins. II. Immunochemical differentiation and classification of kappa-chains. J. Exp. Med. 130:1295-1311, 1969.

26.Solomon, A. and McLaughlin, C.L. Biosynthesis of low molecular weight (7S) and high molecularweight (19S) immunoglobulin M. J. Clin. Invest. 49:150-160, 1970.

27.Buonocore, E., Solomon, A., and Kerley, H.E. Pseudomyeloma. Radiology. 95:41-46, 1970.

28.Solomon, A. Bence Jones protein: A molecular entity for studies on the structural and geneticcontrol of antibody specificity. J.Mt.Sinai Med.37:466-476, 1970 (Festschrift forDr. Alexander B. Gutman).

29.Solomon, A., McLaughlin, C.L., and Steinberg, A.G. Bence Jones proteins and light chains ofimmunoglobulins. III. Inv antigenicity: A genetic expression with serologic dependency on the intact kappa light chain molecule. Immunochemistry.7:709-713, 1970.

30.Solomon, A. and McLaughlin, C.L. Bence Jones proteins and light chains of immunoglobulins. IV.Immunochemical differentiation among proteins within each of the three established -chain classes.J. Immunol.106:120-127, 1971.

1. Solomon, A., McLaughlin, C.L., Wei, C.H., and Einstein, J.R. Bence-Jones proteins and light chains of immunoglobulins. V. X-ray crystallographic investigation of the amino-terminal half of a  Bence-Jones protein. J. Biol. Chem.245:5289-5291, 1970.

32.McLaughlin, C.L. and Solomon, A. Bence Jones proteins and light chains of immunoglobulins. VI. Immunochemical detection of interclass similarities among -chains. J. Immunol. 107:1699-1705, 1971.

33.Rush, E.A., McLaughlin, C.L., and Solomon, A. The essentiality of decyclization of pyrrolidone- carboxylic acid prior to utilization in protein biosynthesis. Cancer Res.31:1134-1139, 1971.

34.McLaughlin, C.L. and Solomon, A. Bence-Jones proteins and light chains of immunoglobulins. VII.Localization of antigenic sites responsible for immunochemical heterogeneity of  chains. J. Biol. Chem. 247:5017-5025, 1972.

35.Solomon, A. and McLaughlin, C.L. Immunoglobulin structure determined from products of plasmacell neoplasms. Semin. Hematol.10:3-17, 1973.

36.Solomon, A. and McLaughlin, C.L. Immunoglobulin disturbances and their clinical significance. Med. Clin. North Am.57:499-516, 1973.

37.McLaughlin, C.L. and Solomon, A. A hidden antigenic site localized to the constant region of lightchains of immunoglobulins. Science . 179:580-582, 1973.

38.Grey, H.M., Colon, S., Solomon, A., and McLaughlin, C.L. Immunoglobulin on the surface of humanlymphocytes. The detection of kappa chain V region determinants on B cells and not on T cells.J. Immunol.111:1923-1925, 1973.

39.Milstein, C.P., Steinberg, A.G., McLaughlin, C.L., and Solomon, A. Amino acid sequence changeassociated with genetic marker Inv(2) of human immunoglobulin. Nature. 248:160-161, 1974.

40.Steinberg, A.G., Milstein, C.P., McLaughlin, C.L., and Solomon, A. Structural studies of an Inv(1,-2)kappa light chain. Immunogenetics. 1:108-117, 1974.

41.Vodopick, H., Chaskes, S.J., Solomon, A., and Stewart, J.A. Transient monoclonal gammopathyassociated with cytomegalovirus infection. Blood. 44:189-195, 1974.

42.McLaughlin, C.L. and Solomon, A. Immunochemical classification of nonisolated light chains ofimmunoglobulins. J. Immunol.113:1369-1372, 1974.

43.Solomon, A., McLaughlin, C.L., and Capra, J.D. Bence Jones proteins and light chains ofimmunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroidtherapy. J. Clin. Invest.55:579-586, 1975.

44.Solomon, A. Cellular regulation of humoral immunity (editorial). N. Engl. J. Med.293:928-929, 1975.

45.Solomon, A. Medical progress: Bence-Jones proteins and light chains of immunoglobulins. Parts Iand II. N. Engl. J. Med. 294:17-23, 91-98, 1976.

46.Solomon, A., Sonoda, T., and Patterson, F.K. Response of metastatic malignant carcinoid tumor toadriamycin (NSC-123127). Cancer Treat. Rep. 60:273-276, 1976.

47.Sonoda, T., Solomon, A., Krauss, S., Cruz, P., Jones, F.S., and Levin, J. Use of prothrombin complexconcentrates in the treatment of a hemophilic patient with an inhibitor of factor VIII. Blood. 47:983- 989, 1976.

48.Longworth, J.W., McLaughlin, C.L., and Solomon, A. Luminescence studies on Bence Jones proteinsand light chains of immunoglobulins and their subunits. Biochemistry. 15:2953-2958, 1976.

49.Solomon, A., Schmidt, W., and Havemann, K. Bence Jones proteins and light chains ofimmunoglobulins. XIII. Effect of elastase-like and chymotrypsin-like neutral proteases derived fromhuman granulocytes on Bence Jones proteins. J. Immunol. 117:1010-1014, 1976.

50.Solomon, A. Bence Jones proteins and light chains of immunoglobulins. XIV. Conformationaldependency and molecular localization of the kappa () and lambda () antigenic determinants.Scand. J. Immunol.5:685-695, 1976.

51.Feizi, T., Lecomte, J., Childs, R., and Solomon, A. Kappa chain (VIII) subgroup-related activity inan idiotypic anti-cold agglutinin serum. Scand. J. Immunol. 5:629-636, 1976.

52.Solomon, A. Bence Jones proteins and light chain fragments: Biochemical and clinical studies. InTopics in Hematology. Seno, S., Takaku, F., and Irino, S., Eds., Excerpta Medica, Amsterdam, 1976,pp. 451-453.

53.Tornyos, K., Silberman, H., and Solomon, A. Phase II study of oral methyl-CCNU and prednisonein previously treated alkylating agent-resistant multiple myeloma. Cancer Treat. Rep. 61:785-787, 1977.

54.Solomon, A. Homogeneous (monoclonal) immunoglobulins in cancer (editorial). Am. J. Med. 63:169-176, 1977.

55.Hübner, K.F., Andrews, G.A., Hayes, R.L., Poggenburg, J.K., and Solomon, A. The use of rare-earthradionuclides and other bone-seekers in the evaluation of bone lesions in patients with multiplemyeloma or solitary plasmacytoma. Radiology. 125:171-176, 1977.

56.Solomon, A. Bence Jones proteins and light chains of immunoglobulins. XVI. Immunochemicalrecognition of the human lambda light-chain constant-region isotype Mcg. Immunogenetics. 5:525-533, 1977.

57.Solomon, A. Detection of chemotherapeutic-associated alterations of monoclonal and polyclonal immunoglobulins in multiple myeloma. In Current Chemotherapy. Siegenthaler, W. and Luthy, R., Eds., Vol. 2, American Society for Microbiology, Washington, D.C., 1977, pp. 1108-1110.

58.Solomon, A. Bence Jones proteins and light chains of immunoglobulins. XV. Effect of corticosteroids on synthesis and excretion of Bence Jones protein. J. Clin. Invest.61:97-108, 1978.

59.Solomon, A. M proteins in cancer (Reply: Letter to the Editor). Am. J. Med.64:1089-1090, 1978.

1. Solomon, A. Possible role of PMN proteases in immunoglobulin degradation and amyloid formation. In Neutral Proteases of Human Polymorphonuclear Leukocytes. Havemann, K. and Janoff, A., Eds., Urban & Schwarzenberg, Baltimore, 1978, pp. 423-438.

61.Solomon, A. and Havemann, K. Bence Jones proteins and light chains of immunoglobulins. XVII.Unique susceptibility of certain -chains to proteolysis by human granulocyte-derived neutral proteases. Immunochemistry.15:453-458, 1978.

62.Schiffer, M., Westholm, F.A., Panagiotopoulos, N., and Solomon, A. Crystallographic data on acomplete -type human Bence-Jones protein. J. Mol. Biol.124:287-290, 1978.

63.Solomon, A., Gramse, M., and Havemann, K. Proteolytic cleavage of human IgG molecules by neutral proteases of polymorphonuclear leukocytes. Eur. J. Immunol.8:782-785, 1978.

64.Krauss, S., Tornyos, K., DeSimone, P., Lowenbraun, S., McKeown, J., Solomon, A., and Sonoda, T.cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lungcancer: A pilot study of the Southeastern Cancer Study Group. Cancer Treat. Rep. 63:391-393, 1979.

65.Krauss, S., Sonoda, T., and Solomon, A. Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C. Cancer. 43:1598-1603, 1979.

66.Solomon, A. Monoclonal immunoglobulins as biomarkers of cancer. In Cancer Markers: Developmental and Diagnostic Significance. Sell, S., Ed., Humana Press, Clifton, New Jersey, 1980,pp. 57-87.

67.Stevens, F.J., Westholm, F.A., Solomon, A., and Schiffer, M. Self-association of humanimmuno- globulin I light chains: Role of the third hypervariable region. Proc. Natl. Acad. Sci. USA. 77:1144-1148, 1980.

68.Kosaka, M. and Solomon, A. Hyperviscosity syndrome associated with an idiopathic monoclonal IgA-rheumatoid factor. Am. J. Med. 69:145-154, 1980.

69.Solomon, A. Current developments in immunoglobulins. InContemporary Hematology/Oncology,Silber, R., Gordon, A.S., LoBue, J. and Muggia, F.M., Eds., Vol. 2, 1981, pp. 399-465.

70.Levy, D.E., Horner, A.A., and Solomon, A. Immunoglobulin-sulfated polysaccharide interactions.The binding of agaropectin and heparin by human IgG proteins. J. Exp. Med. 153:883-896, 1981.

71.Whitson, M.E., Griffin, G.D., Novelli, G.D., and Solomon, A. In vitro sensitization of humanlymphocytes to a myeloma cell-related antigen. Cell Immunol.60:489-497, 1981.

72.Stevens, F.J., Westholm, F.A., Panagiotopoulos, N., Schiffer, M., Popp, R.A., and Solomon, A.Characterization and preliminary crystallographic data on the VL-related fragment of the human IBence Jones protein Wat. J. Mol. Biol. 147:185-193, 1981.

73.Stevens, F.J., Westholm, F.A., Panagiotopoulos, N., Solomon, A., and Schiffer, M. Preliminarycrystallographic data on the human III Bence Jones protein dimer Cle. J. Mol. Biol. 147:179-183, 1981.

74.Solomon, A. Bence Jones proteins: Malignant or benign? (editorial). N. Engl. J. Med. 306:605-607, 1982.

75.Solomon, A., Frangione, B., and Franklin, E.C. Bence Jones proteins and light chains ofimmunoglobulins. Preferential association of the VVI subgroup of human light chains withamyloidosis AL(). J. Clin. Invest.70:453-460, 1982.

76.Koopman, W.J., Schrohenloher, R.E., and Solomon, A. A quantitative assay for IgA rheumatoidfactor. J. Immunol. Methods. 50:89-98, 1982.

77.Griffin, G.D., Owen, B.A., Atchley, C.E., Novelli, G.D., and Solomon, A. Decreased immunoglobulin production by a human lymphoid cell line following melphalan treatment. Cancer Res.42:4505-4510, 1982.

78.Ledford, D.K., Goñi, F., Pizzolato, M., Franklin, E.C., Solomon, A., and Frangione, B. Preferentialassociation of IIIb light chains with monoclonal human IgM auto-antibodies. J.Immunol.131: 1322-1325, 1983.

79.Frangione, B., Moloshok, T., and Solomon, A. Primary structure of the variable region of a humanVI light chain: Bence Jones protein SUT. J. Immunol.131:2490-2493, 1983.

80.Greenstein, J.L., Solomon, A., and Abraham, G.N. Monoclonal antibodies reactive with idiotypicand variable-region specific determinants on human immunoglobulins. Immunology.51:17-25, 1984.

81.Klöbeck, H.-G., Solomon, A., and Zachau, H.G. Contribution of human VII germ-line genes to light-chain diversity. Nature. 309:73-76, 1984.

82.Pons-Estel, B., Goñi, F., Solomon, A., and Frangione, B. Sequence similarities among IIIb chains of monoclonal human IgM autoantibodies. J. Exp. Med.160:893-904, 1984.

83.Solomon, A. Light chains of human immunoglobulins. Methods Enzymol.116:101-121, 1985.

84.Schrohenloher, R.E., Koopman, W.J., Moldoveanu, Z., and Solomon, A. Activity of rheumatoidfactors of different molecular sizes: Comparison of autologous monomeric and polymericmonoclonal IgA rheumatoid factors. J. Immunol.134:1469-1474, 1985.

85.Frangione, B., Moloshok, T., Prelli, F., and Solomon, A. Human  light-chain constant region geneCMor: The primary structure of VI Bence Jones protein Mor. Proc. Natl. Acad. Sci.USA. 82:3415-3419, 1985.

86.Klobeck, H.-G., Meindl, A., Combriato, G., Solomon, A., and Zachau, H.G. Human immunoglobulinkappa light chain genes of subgroups II and III. Nucleic Acids Res.13:6499-6513, 1985.

87.Chang, C-H., Short, M.T., Westholm, F.A., Stevens, F.J., Wang, B-C., Furey, W., Jr., Solomon, A.,and Schiffer, M. Novel arrangement of immunoglobulin variable domains: X-ray crystallographicanalysis of the -chain dimer Bence-Jones protein Loc. Biochemistry. 24:4890-4897, 1985.

88.Ghiso, J., Solomon, A., and Frangione, B. Association of human  light chain V/J/C segments:Serologic analysis and primary structure of the VI Bence Jones protein THO. J.Immunol. 136: 716-719, 1986.

89.Solomon, A., Kyle, R.A., and Frangione, B. Light chain variable region subgroups of monoclonalimmunoglobulins in amyloidosis AL. InAmyloidosis. G.G. Glenner, E.F. Osserman, E.P. Benditt, E. Calkins, A.S. Cohen, and D. Zucker-Franklin, Eds., Plenum Press, New York, 1986, pp. 449-462.

90.Solomon, A. Clinical implications of monoclonal light chains. Semin. Oncol.13:341-349,1986.

91. Prelli, F., Tummolo, D., Solomon, A., and Frangione, B. Novel human light chain V segment: Serological and structural analyses of the III-like Bence Jones protein and IgG light chain REE.J. Immunol.136:4169-4173, 1986.

92.Solomon, A. Light chains of immunoglobulins: Structural-genetic correlates. Blood. 68:603-610, 1986.

93.Walker, M.R., Solomon, A., Ling, N.R., Brown, B., Lowe, J.A., Hardie, D., and Jefferis, R. Immunogenic and antigenic epitopes of immunoglobulins. XVIII. Subpopulations of human lambdachains defined with a panel of monoclonal antibodies. Immunology.59:467-471, 1986.

94.Silverman, G.J., Carson, D.A., Solomon, A., and Fong, S. Human kappa light chain subgroup analysiswith synthetic peptide-induced antisera. J. Immunol. Methods.95:249-257, 1986.

95.Davidson, A., Preud'homme, J-L., Solomon, A., Chang, M-D.Y., Beede, S., and Diamond, B. Idiotypic analysis of myeloma proteins: anti-DNA activity of monoclonal immunoglobulins bearing an SLE idiotype is more common in IgG than IgM antibodies. J. Immunol.138:1515-1518, 1987.

96.Solomon, A. and Weiss, D.T. Serologically defined V region subgroups of human  light chains. J. Immunol.139:824-830, 1987.

97.Livneh, A., Preud'homme, J-L., Solomon, A., and Diamond, B. Preferential expression of the systemic lupus erythematosus-associated idiotype 8.12 in sera containing monoclonal immunoglobulins. J. Immunol.139:3730-3733, 1987.

98.Solomon, A. and Weiss, D.T. A perspective of plasma cell dyscrasias: Clinical implications ofmonoclonal light chains in renal disease. In The Kidney in Plasma Cell Dyscrasias. L. Minetti, G.D'Amico, and C. Ponticelli, Eds., Kluwer Academic Publishers, Dordrecht, The Netherlands, 1988,pp. 3-18.

99.Walker, M.R., Solomon, A., Weiss, D.T., Deutsch, H.F., and Jefferis, R. Immunogenic and antigenicepitopes of Ig. XXV. Monoclonal antibodies that differentiate the Mcg+/Mcg-and Oz+/Oz-C regionisotypes of human  L chains. J. Immunol.140:1600-1604, 1988.

100.Goñi, F.R., Chen, P.P., McGinnis,D., Arjonilla, M.L., Fernandez, J., Carson, D., Solomon, A.,Mendez, E., and Frangione, B. Structural and idiotypic characterization of the L chains of human IgMautoantibodies with different specificities. J. Immunol.142:3158-3163, 1989.

101.Schiffer, M., Ainsworth, C., Xu, Z.-B., Carperos, W., Olsen, K., Solomon, A., Stevens, F.J., and Chang, C.-H. Structure of a second crystal form of Bence-Jones protein Loc: Strikingly differentdomain associations in two crystal forms of a single protein. Biochemistry. 28:4066-4072, 1989.

102.Davidson, A., Smith, A., Katz, J., Preud'homme, J-L., Solomon, A., and Diamond, B. A cross-reactiveidiotype on anti-DNA antibodies defines a H chain determinant present almost exclusively on IgGantibodies. J. Immunol.143:174-180, 1989.

103.Arsen'eva, E.L., Bogacheva, G.T., Solomon, A., and Rokhlin, O.V. Antigen determinants on humanimmunoglobulin  chain constant domains detected by monoclonal antibodies. Mol. Biol.23:1227-1233, 1989.

104.Arsen'eva, E.L., Bogacheva, G.T., Solomon, A., Weiss, D.T., and Rokhlin, O.V. Analysis of humanimmunoglobulin  light chain antigenic structure using monoclonal antibodies. Mol. Biol.24:101-109, 1990.

105.Buxbaum, J.N., Chuba, J.V., Hellman, G.C., Solomon, A., and Gallo, G.R. Monoclonal immuno- globulin deposition disease: Light chain and heavy chain deposition diseases and their relationto light chain amyloidosis. Ann. Intern. Med. 112:455-464, 1990.

106.Eulitz, M., Weiss, D.T., and Solomon, A. Immunoglobulin heavy-chain-associated amyloidosis. Proc. Natl. Acad. Sci.USA. 87:6542-6546, 1990.

107.Solomon, A., Weiss, D.T., Macy, S.D., and Antonucci, R.A. Immunocytochemical detection ofkappa and lambda light chain V region subgroups in human B cell malignancies. Am. J. Pathol. 137:855-862, 1990.

108.Caudle, M.R., Dodd, S., and Solomon, A. Multiple myeloma in pregnancy: A case report. ObstetGynecol. 75:516-518, 1990.

109.Solomon, A. and Weiss, D.T. Experimental production of human amyloidosis AL. InAmyloid andAmyloidosis 1990. J.B. Natvig, . Frre, G. Husby, A. Husebekk, B. Skogen, K. Sletten, and P.Westermark, Eds., Kluwer Academic Publishers, Dordrecht, The Netherlands, 1991, pp. 193-196.

110.Eulitz, M., Breuer,M., Eblen, A., Weiss, D.T., and Solomon, A. Production of amyloidogenicpeptides from human immunoglobulin light (L)-chains. InAmyloid and Amyloidosis 1990. J.B.Natvig, . Frre, G. Husby, A. Husebekk, B. Skogen, K. Sletten, and P. Westermark, Eds., KluwerAcademic Publishers, Dordrecht, The Netherlands, 1991, pp. 505-510.

111.Silvestris, F., Rots, N., Yancey, W., Jr., Malone, C., Searles, R., Solomon, A., and Williams, R.C., Jr. Monoclonal antibodies against human anti-F(ab')2 antibodies react with light chain epitopes. Clin.Immunol. Immunopathol. 59:139-155, 1991.

112.Eulitz, M., Murphy, C., Weiss, D.T., and Solomon, A. Serological and chemical differentiation ofhuman III light chain variable regions. J. Immunol.146:3091-3096, 1991.

113.Solomon, A., Weiss, D.T., and Kattine, A.A. Nephrotoxic potential of Bence Jones proteins. N.Engl. J. Med. 324:1845-1851, 1991.

114.Stevens, F.J., Solomon, A., and Schiffer, M. Bence Jones Proteins: A powerful tool for thefundamental study of protein chemistry and pathophysiology. Biochemistry. 30:6803-6805, 1991.

115.Solomon, A., Weiss, D.T., and Pepys, M.B. Induction in mice of human light-chain-associatedamyloidosis (AL amyloidosis). Am. J. Pathol.140:629-637, 1992.

116.Nilson, B., Solomon, A., Björck, L., and Åkerström, B. Protein L from peptostreptococcus magnus binds to the kappa light chain variable domain. J. Biol. Chem. 267:2234-2239, 1992.

117.Kanangat, S., Solomon, A., and Rouse, B.T. Use of quantitative polymerase chain reaction to quantitate cytokine messenger RNA molecules. Mol. Immunol.29:1229-1236, 1992.

118.Daniel, S.L., Brenner, C.A., Legendre, A.M., Solomon, A., and Rouse, B.T. Feline cytokines TNF  and IL-1 : PCR cloning and sequencing of cDNA. Anim. Biotechnol. 3:281-297, 1992.

119.Solomon, A., Weiss, D.T., and Williams, T.K. Experimental model of human light-chain-associated disease. Curr. Top. Microbiol. Immunol.182:261-267, 1992.

120.Williams, R., Malone, C., and Solomon, A. Conformational dependency of human IgG heavy-chain-associated Gm allotypes. Mol. Immunol.30:341-351, 1993.

121.Abe, M., Goto, T., Kennel, S.J., Wolfenbarger, D., Macy, S.D., Weiss, D.T., and Solomon, A. Production and immunodiagnostic applications of anti-human light chain monoclonal antibodies. Am. J. Clin. Pathol.100:67-74, 1993.

122.Abe, M., Goto, T., Wolfenbarger, D., Weiss, D.T., and Solomon, A. Novel immunization protocol and ELISA screening methods used to obtain and characterize monoclonal antibodies specific for human light chain variable-region subgroups. Hybridoma.12:475-483, 1993.

123.Solomon, A. and Weiss, D.T. Ominous consequences of immunoglobulin deposition. N. Engl. J. Med.329:1422-1424, 1993.

124.Solomon, A., Weiss, D.T., and Murphy, C. Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis). Am. J. Hematol.45:171-176, 1994.

125.Abe, M., Ozaki, S., Wolfenbarger, D., deBram-Hart, M., Weiss, D.T., and Solomon, A. Variable-region subgroup distribution among -type immunoglobulins in normal human serum. J. Clin. Lab. Anal. 8:4-9, 1994.

126.Solomon, A. and Weiss, D.T. AL amyloidosis. InAmyloid and Amyloidosis 1993. R. Kisilevsky, M. Benson, B. Frangione, J. Gauldie, T. Muckle, and I. Young, Eds., Parthenon Publishing, New York, 1994, pp. 200-205.

127.Solomon, A., Weiss, D.T., and Murphy, C. Heavy-chain-associated amyloidosis (AH amyloidosis). InAmyloid and Amyloidosis 1993. R. Kisilevsky, M. Benson, B. Frangione, J. Gauldie, T. Muckle, and I. Young, Eds., Parthenon Publishing, New York, 1994, pp. 212-214.

128.Ozaki, S., Abe, M., Wolfenbarger, D., , D.T, and Solomon, A. Preferential expression of human -light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia. Clin. Immunol. Immunopathol.71:183-189, 1994.

129.Fang, Q., Kannapell, C.C., Gaskin, F., Solomon, A., Koopman, W.J., and Fu, S.M. Human rheumatoid factors with restrictive specificity for rabbit IgG: Auto- and multi-reactivity, diverse VH gene segment usage and preferential usage of VIIIb. J. Exp. Med. 179:1445-1456, 1994.

130.Ch'ang, L-Y., Yen, C-P., Besl, L., Schell, M., and Solomon, A. Identification and characterization of a functional human Ig VVI germline gene. Mol. Immunol. 31:531-536, 1994.